Abstract
OBJECTIVES: Despite the considerable and growing body of research about the clinical effectiveness of long-term psychoanalytic treatment, relatively little attention has been paid to economic evaluations, particularly with reference to the broader range of societal effects. In this cost-utility study, we examined the incremental cost-effectiveness ratio (ICER) of psychoanalysis versus psychoanalytic psychotherapy.
METHODS: Incremental costs and effects were estimated by means of cross-sectional measurements in a cohort design (psychoanalysis, n = 78; psychoanalytic psychotherapy, n = 104). Quality-adjusted life-years (QALYs) were estimated for each treatment strategy using the SF-6D. Total costs were calculated from a societal perspective (treatment costs plus other societal costs) and discounted at 4 percent. Psychoanalysis was more costly than psychoanalytic psychotherapy, but also more effective from a health-related quality of life perspective. The ICER--that is, the extra costs to gain one additional QALY by delivering psychoanalysis instead of psychoanalytic psychotherapy--was estimated at 52,384 euros per QALY gained.
CONCLUSIONS: Our findings show that the cost-utility ratio of psychoanalysis relative to psychoanalytic psychotherapy is within an acceptable range. More research is needed to find out whether cost-utility ratios vary with different types of patients. We also encourage cost-utility analyses comparing psychoanalytic treatment to other forms of (long-term) treatment.
Original language | English |
---|---|
Pages (from-to) | 3-10 |
Number of pages | 8 |
Journal | International Journal of Technology Assessessment in Health Care |
Volume | 26 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2010 |
Keywords
- Adult
- Age Factors
- Cohort Studies
- Cost of Illness
- Cost-Benefit Analysis
- Cross-Sectional Studies
- Depressive Disorder
- Female
- Humans
- Male
- Personality Disorders
- Psychoanalysis
- Psychoanalytic Therapy
- Quality of Life
- Quality-Adjusted Life Years
- Sex Factors
- Socioeconomic Factors
- Time Factors
- Clinical Trial
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't